CytoDyn's Leronlimab Suffers Refuse To File Letter; US FDA Concerned About Dosing, Manufacturing

 
• By Jessica Merrill
  
Stop sign
A refuse to file letter has stopped review of leronlimab by the US FDA until CytoDyn can provide more data.

More from Product Reviews

More from Pink Sheet